Table 1.
Baseline Characteristics of Dasatinib vs. Imatinib: Serum Glucose Values
| Dasatinib | Imatinib | *P-value | |
|---|---|---|---|
| Number | 12 | 26 | |
| Male | 7 (58%) | 17 (65%) | 0.728 |
| Race, White | 10 (83%) | 24 (92%) | 0.577 |
| Malignancy | |||
| CML a | 9 (75%) | 13 (50% ) | 0.178 |
| ALL a | 2 (17%) | 1 (4%) | 0.230 |
| GIST a | 1 (8%) | 11 (42%) | 0.060 |
| Melanoma | 0 | 1 (4%) C | >0.99 |
| Age at Diagnosis | 61.7 ± 10.9 | 64.0 ± 11.0 | 0.304 |
| TKI prior to dasatinib/imatinib | 4/12 (33%) | 0 | 0.007 |
| Baseline Glucose (mg/dL) | 145 ± 48 | 132 ± 39 | 0.414 |
| On Insulin | 4 (33%) | 7 (25%) | 0.714 |
| Average Total Daily Units | 71 ± 47 | 67 ± 52 | 0.907 |
| On oral agents | 10 (83%) | 19 (73%) | 0.689 |
| Number of agents | 1.2 ± 0.8 | 1.0 ± 0.8 | 0.568 |
| Baseline Weight (kg) | 98.5 ± 23.5 | 95.6 ± 23.0 | 0.728 |
*
P-values obtained using a 2-tailed two-sample t-test assuming unequal variances for continuous variables, or Fisher’s exact test for categorical variables
a
CML, chronic myelogenous leukemia; ALL, Acute lymphoblastic leukemia; GIST, Gastrointestinal Stromal Tumor.